To determine whether this characteristic heightens bleeding risk in patients with renal insufficiency, researchers in Connecticut compared bleeding rates with enoxaparin and UFH in a retrospective ...

The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...

Pedraza-Cruz, P. , Varghese, M. , DiGiacomo, D. , Spencer, C. and Horani, O. (2025) Adrenal Crisis Secondary to Bilateral Adrenal Hemorrhage in a Patient with Hypercoagulable Disorder. Case Reports in ...

The following is a summary of “Treating chronic kidney disease in Danish primary care: results from the observational ATLAS study,” published in the February 2025 issue of BMC Primary Care by ...

An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...

"Heart failure and kidney failure often go hand in hand," he told Newsweek, adding that the kidneys control the way the body handles salt and water. If they are not getting rid of these substances ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

There is no standard approach to starting kidney transplant evaluations in patients referred from dialysis facilities to ...

Dr. Katy Beckermann discusses how a Fotivda and Opdivo combination for renal cell carcinoma compared with Fotivda alone based ...

Now aged 32, the entrepreneur is sharing his story to raise awareness of kidney disease, which affects 35.5 million Americans, according to the American Kidney Fund. Blake Shusterman, a ...

Obinutuzumab B-cell depleting therapy is more effective than standard care in treating patients with active proliferative lupus nephritis.